A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves in vivo PK in mice and monkeys.

Author: Ciming KANG ¹ ; Lin XIA ¹ ; Yuanzhi CHEN ¹ ; Tianying ZHANG ¹ ; Yiwen WANG ¹ ; Bing ZHOU ¹ ; Min YOU ¹ ; Quan YUAN ¹ ; Chi-Meng TZENG ² ; Zhiqiang AN ¹ ; Wenxin LUO ³ ; Ningshao XIA ¹
Author Information

1. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, School of Life Science, Xiamen University, Xiamen, 361105, China.
2. Key Laboratory for Cancer T-Cell Theranostics and Clinical Translation (CTCTCT), Translational Medicine Research Center, School of Pharmaceutical Science, Xiamen University, Xiamen, 361105, China.
3. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, School of Life Science, Xiamen University, Xiamen, 361105, China. wxluo@xmu.edu.cn.
Publication Type:Letter
MeSH: Animals; Antibodies, Monoclonal; pharmacokinetics; therapeutic use; Antibodies, Viral; therapeutic use; Hepatitis B virus; immunology; Histocompatibility Antigens Class I; metabolism; Humans; Macaca fascicularis; Mice; Protein Binding; Protein Engineering; Receptors, Fc; metabolism
From: Protein & Cell 2018;9(1):130-134
CountryChina
Language:English